Skip to content

Cristina Cusin

Harvard University

2 papers in the library · 18 citations · publishing 2019-2026

Papers

Evolving Issues in the Treatment of Depression

JAMA May 24, 2019 Ole Köhler‐forsberg, Cristina Cusin, Andrew A. Nierenberg 18 citations

Recent evidence shows that several nonpharmacological and drug therapies can benefit people with major depressive disorder. Effective options include exercise, a Mediterranean diet with structured dietary support, ketamine and esketamine, anti-inflammatory drugs, brexanolone, and psilocybin.

DOI: 10.1001/jama.2019.4990 Psilocybin Ketamine Major depressive disorder Depression economics +8

Comparative effectiveness and safety of esketamine versus injectable racemic ketamine and oral antidepressants for major depressive disorder: A population-based target trial emulation.

Journal of affective disorders August 1, 2026 Ching-Hua Julie Lee, Yunzhe Qian, Weiqun Yu et al.

Compared with injectable ketamine, esketamine was linked to higher risks of suicidal ideation (24% increase), generalized anxiety disorder (55% increase), insomnia (25% increase), and cardiac arrest (57% increase). Compared with oral antidepressants in treatment-resistant depression, esketamine was associated with lower risks of suicidal ideation (11% decrease), suicide attempt (29% decrease), and generalized anxiety disorder (18% decrease), but a higher risk of cardiac arrest (109% increase). Injectable ketamine showed a more favorable safety and effectiveness profile than esketamine. Head-to-head clinical trials are needed to validate these findings.

DOI: 10.1016/j.jad.2026.121487 Full text Esketamine Major depressive disorder Treatment-resistant depression Outcomes +1